Co-hosted by HealthEconomics.com, this unique, live streamed panel webinar will feature four of our top HEOR thought leaders in conversation with moderator and HealthEconomics.com CEO Patti Peeples.
Joining Patti will be Dr. Peter Neumann, Precision Xtract Consultant and Director of the Center for the Evaluation of Value and Risk in Health (CEVR), Institute for Clinical Research and Health Policy Studies at Tufts Medical Center; Dr. Anupam Bapu Jena, Precision Xtract Scientific Advisor and Associate Professor at Harvard Medical School; Dr. Jeroen Jansen, […]
Recent years have brought significant innovation in potentially curative therapies for several diseases. By 2025, the FDA anticipates approving 10 to 20 cell and gene therapy products per year, many of which are intended to be one-time curative treatments.
In the latest edition of Journal of Clinical Pathways, Precision experts Chris Dillon, Chrysanthe Peteros and Larry Blandford examine the expanding role of hub support services in the pharmaceutical marketplace, emphasizing their importance as increasingly complex therapies requiring higher degrees of specialization and flexibility are launched.
For more information, or to learn how to change your cookies preferences, please click here.